In a news release dated March 29, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mavenclad® (cladribine) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval is for individuals with relapsing-remitting MS (RRMS) and for individuals with active secondary-progressive MS (SPMS).

In a news release dated March 26, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mayzent® (siponimod) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval includes individuals with clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Mayzent is the only disease-modifying […]

The opening months of 2019 saw significant research advances on many fronts in multiple sclerosis (MS). A sophisticated analysis of data using healthcare claims found that the number of people in the United States living with MS is more than twice as high as previously estimated. Dietary studies sounded a cautionary note for people with MS drinking soda and many other sweetened beverages, and a hopeful note on the potential for flavonoid-rich cocoa to reduce MS-associated fatigue. A promising stem-cell therapy is moving forward in the clinical-trials process, while the FDA is considering whether to approve a new disease-modifying therapy (DMT).

The Multiple Sclerosis Association of America (MSAA) is proud to recognize March as Multiple Sclerosis (MS) Awareness Month. This year, MSAA’s awareness campaign focuses on MS and the Family, with specific topics addressing: Relationships and MS, and Spotlighting Care Partner Needs. MSAA invites you to participate in weekly awareness activities, which include: Relationships and MS […]

The Multiple Sclerosis Association of America (MSAA) is pleased to announce the newest member of its Board of Directors, Alexandra von Plato of Gladwyne, Pennsylvania. Ms. von Plato is Chief Executive Officer of Publicis Health, where she leads global teams of nearly 4,000 professionals with expertise in advertising and branding, strategic communications, digital media and […]

This installment of “What’s New in MS Research” highlights the breadth of that research, as the nine studies reported below examine everything from a possible link between food allergies and MS disease activity, to the promise of stem cell transplantation in people who have not obtained a satisfactory response from multiple disease-modifying therapies (DMTs). Important studies on the potential causes of MS, the role of patient preferences in drug selection and adherence, and other topics also are covered.

This year’s gathering was held in Berlin, Germany, October 10-12, where the findings were presented from hundreds of studies on topics ranging from the safety and effectiveness of investigational medications to the role of diet in controlling symptoms of MS.

Research into the causes, diagnosis, impact, and management of multiple sclerosis (MS) continues to move forward on a broad front and at a rapid pace. While many advances are announced at medical meetings, such as the annual gatherings of the American Academy of Neurology (AAN), American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Consortium of Multiple Sclerosis Centers (CMSC), and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), other findings are reported in medical journals throughout the year.

In the event of a disaster in your area, make sure you can access emergency services.